National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings, 33942-33943 [2018-15280]
Download as PDF
<![CDATA[
amozie on DSK3GDR082PROD with NOTICES1
33942
Federal Register / Vol. 83, No. 138 / Wednesday, July 18, 2018 / Notices
national security. The changes are as
follows.
I. Under AN.10 Organization, delete
all of the components and replace with
the following:
A. Immediate Office of the Assistant
Secretary for Preparedness and
Response (ANA)
B. Office of Biomedical Advanced
Research and Development Authority
(ANB)
C. Office of the Principal Deputy
Assistant Secretary (ANC)
D. Office of the Deputy Assistant
Secretary Incident Command and
Control (ANG)
II. Delete AN.20 Functions, in its
entirety and replace with the following:
Section AR.20 Functions.
A. Immediate Office of the Assistant
Secretary for Preparedness and
Response: The Immediate Office of the
Assistant Secretary for Preparedness
and Response (IO/ASPR) is headed by
the Assistant Secretary, who provides
leadership and executive and strategic
direction for the ASPR organization.
The Assistant Secretary is the principal
advisor to the Secretary on all matters
related to Federal public health and
medical preparedness and response for
public health emergencies. The
Assistant Secretary is responsible for
carrying out ASPR’s mission and
implementing the functions of ASPR.
The IO/ASPR (1) ensures development
and maintenance of liaison
relationships with HHS operating and
staff divisions and represents HHS at
interagency meetings, as required; (2)
establishes and maintains effective
communications and outreach guidance
and support for all external
communications, including legislative
and executive branch questions and
inquiries, and serves as the principal
advisor to the ASPR on all legislative
strategies to fulfill the Office of the
ASPR and the HHS mission under
section 2811 and other relevant sections
of the Public Health Service Act, as
amended; (3) oversees advanced
research, development and procurement
of qualified countermeasures, security
countermeasures and qualified
pandemic or epidemic products; (4)
coordinate with relevant federal officials
to ensure integration of federal
preparedness and response activities for
public health emergencies; (5) manages
correspondence control for the Assistant
Secretary; and (6) coordinates the
strategic and operational activities for
public health preparedness response
and recovery.
B. Office of Biomedical Advance
Research and Development Authority
(ANB). The Office of Biomedical
VerDate Sep<11>2014
19:19 Jul 17, 2018
Jkt 244001
Advanced Research and Development
Authority (BARDA), established in
April 2007 in response to the Pandemic
and All-Hazards Preparedness Act of
2006, serves preparedness and response
roles to provide medical
countermeasures (MCM) in order to
mitigate the medical consequences of
chemical, biological, radiological, and
nuclear (CBRN) threats and agents and
emerging infectious diseases, including
pandemic influenza. BARDA executes
this mission by facilitating research,
development, innovation, and
acquisition of MCM and expanding
domestic manufacturing infrastructure
and surge capacity of these MCM.
BARDA is headed by a Deputy
Assistant Secretary, and includes the
following components:
• Division of Influenza (ANB1)
• Division of Emerging Infectious
Diseases (ANB2)
• Division of Chemical, Biological,
Radiological and Nuclear Threats
(ANB3)
• Division of Strategic Science and
Technology (ANB4)
• Division of Regulatory and Quality
Affairs (ANB5)
• Division of Research, Innovation and
Ventures (ANB6)
C. Office of the Principal Deputy
Assistant Secretary (ANC). The Office of
the Principal Deputy Assistant Secretary
(OPDAS) is responsible for providing a
well-integrated infrastructure that
supports the Department’s capabilities
to prevent, prepare for, respond to and
recover from natural public health and
medical threats and emergencies.
OPDAS leads the preparedness and
response activities required to
coordinate public health and healthcare
response systems and activities with
relevant federal, state, tribal, territorial,
local, and international communities
under the National Response
Framework and Emergency Support
Annexes #8, #6 and #14. OPDAS is
responsible for the execution of
business management operations and
managing coordination. OPDAS
provides for the facility, logistics,
information technology and
infrastructure support services
necessary to maintain day-to-day
operations of ASPR, including functions
of Human Resources, Organization and
Employee Development, Ethics, United
States Public Health Service (USPHS)
liaison, acquisitions management,
contracts, grants, and all financial
planning and analysis.
The Office of the Principal Deputy
Assistant Secretary is headed by the
Principal Deputy Assistant Secretary,
and includes the following components:
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
• Division of Management Finance and
Human Capital (ANC1)
• Division of Emergency Management
and Medical Operations (ANC2)
• Division of Resource Management
(ANC3)
D. Deputy Assistant Secretary
Incident Command and Control (ANG):
The Deputy Assistant Secretary (DAS/
ICC) is responsible for the policy
development, planning analysis,
requirements and strategic planning.
DAS/ICC manages and operates the HHS
Secretary’s Operation Center (SOC),
intelligence, security, information
management and is also responsible for
the HHS Continuity of Operations
(COOP) and the development of the
ASPR COOP Plan. The Office of the
Assistant Secretary Incident Command
and Control (DAS/ICC) is headed by the
Deputy Assistant Secretary Incident
Command and Control, and includes the
following components:
• Division of Security Intelligence and
Information Management
• Division of Strategy, Policy, Planning
and Requirements
III. Delegations of Authority. All
delegations and redelegations of
authority made to officials and
employees of affected organizational
components will continue in them or
their successors pending further
redelegation, provided they are
consistent with this reorganization.
Alex M. Azar II,
Secretary.
[FR Doc. 2018–15310 Filed 7–17–18; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\18JYN1.SGM
18JYN1
amozie on DSK3GDR082PROD with NOTICES1
Federal Register / Vol. 83, No. 138 / Wednesday, July 18, 2018 / Notices
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Sleep Apnea
Treatment With Positive Airway Pressure for
Prevention of Diabetes Mellitus.
Date: July 27, 2018.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Bariatric SurgeryRelated Applications.
Date: July 30, 2018.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Paul A. Rushing, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–8895,
rushingp@extra.niddk.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Type 1 Diabetes
Small Business Applications.
Date: August 6, 2018.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Ryan G. Morris, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7015, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, 301–594–4721,
ryan.morris@nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; RFA–DK–17–035
Microphysiological Systems (MPS) for
Modeling Diabetes (UG3/UH3).
Date: August 7, 2018.
Time: 11:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
VerDate Sep<11>2014
19:19 Jul 17, 2018
Jkt 244001
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Ann A. Jerkins, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7119, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, 301–594–2242,
jerkinsa@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity Research.
Date: August 8, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; RFA–DK–17–030
Advancement of Cell Replacement Therapies
for Type 1 Diabetes (R43/R44).
Date: August 8, 2018.
Time: 12:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Ann A. Jerkins, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7119, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, 301–594–2242,
jerkinsa@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK–R01
Telephone Review.
Date: August 10, 2018.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Xiaodu Guo, MD, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7023, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–4719,
guox@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
33943
Dated: July 12, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy/
[FR Doc. 2018–15280 Filed 7–17–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, Center
for Genetic Studies (7797).
Date: July 25, 2018.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, DHHS, 6001
Executive Blvd., Room 4238, MSC 9550,
Bethesda, MD 20892–9550, 301–827–5819,
gm145a@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program No.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: July 12, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–15279 Filed 7–17–18; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\18JYN1.SGM
18JYN1
]]>Agencies
[Federal Register Volume 83, Number 138 (Wednesday, July 18, 2018)]
[Notices]
[Pages 33942-33943]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15280]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
[[Page 33943]]
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Sleep Apnea Treatment
With Positive Airway Pressure for Prevention of Diabetes Mellitus.
Date: July 27, 2018.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Paul A. Rushing, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8895, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Bariatric Surgery-
Related Applications.
Date: July 30, 2018.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Paul A. Rushing, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-8895, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Type 1 Diabetes Small
Business Applications.
Date: August 6, 2018.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Ryan G. Morris, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7015, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, 301-
594-4721, [email protected].
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; RFA-DK-17-035
Microphysiological Systems (MPS) for Modeling Diabetes (UG3/UH3).
Date: August 7, 2018.
Time: 11:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Ann A. Jerkins, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301-
594-2242, [email protected].
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; Time-Sensitive Obesity
Research.
Date: August 8, 2018.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Michele L. Barnard, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7353, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301)
594-8898, [email protected].
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; RFA-DK-17-030
Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/
R44).
Date: August 8, 2018.
Time: 12:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Ann A. Jerkins, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7119, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, 301-
594-2242, [email protected].
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel; NIDDK-R01 Telephone
Review.
Date: August 10, 2018.
Time: 11:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Xiaodu Guo, MD, Ph.D., Scientific Review
Officer, Review Branch, DEA, NIDDK, National Institutes of Health,
Room 7023, 6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301)
594-4719, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes of Health, HHS)
Dated: July 12, 2018.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy/
[FR Doc. 2018-15280 Filed 7-17-18; 8:45 am]
BILLING CODE 4140-01-P
